Choline‐positron emission tomography/ CT  in patients with relapsing prostate cancer: to be performed with therapeutic consequences only | Zendy

Heidenreich Axel | Zendy

Premium

Choline‐positron emission tomography/ CT in patients with relapsing prostate cancer: to be performed with therapeutic consequences only

Author(s) -

Heidenreich Axel

Publication year - 2015

Publication title -

bju international

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.773

H-Index - 148

eISSN - 1464-410X

pISSN - 1464-4096

DOI - 10.1111/bju.12995

Subject(s) - medicine , prostatectomy , prostate cancer , positron emission tomography , context (archaeology) , brachytherapy , androgen deprivation therapy , choline , radiation therapy , prostate , nuclear medicine , radiology , cancer , paleontology , biology

18F-choline positron emission tomography (PET)/C T has become a modern imaging technique in men with prostate cancer and biochemical relapse after local treatment with curative intent (radical prostatectomy, external beam/ intensity-modulated radiation therapy, brachytherapy) in order to differentiate between local, locoregional and systemic relapse. Although 18F-choline PET/CT will probably be replaced by prostate-specific membrane antigen-PET/CT in the near future, the present paper by Rodada-Marina et al. [1] is important for daily routine because the authors attempt to define the current role of 18F-choline PET/CT in the diagnostic algorithm of men with relapsing PSA and to define specific patient cohorts in whom 18F-choline PET/CT might have a significant impact in the decision-making process regarding the most appropriate treatment.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research